Introduction:Recently published large randomized controlled trials,START,TEMPRANO and HPTN 052 show the clinical benefit of early initiation of antiretroviral treatment(ART)in HIV-infected persons and in reducing HIV ...Introduction:Recently published large randomized controlled trials,START,TEMPRANO and HPTN 052 show the clinical benefit of early initiation of antiretroviral treatment(ART)in HIV-infected persons and in reducing HIV transmission.The trials influenced the World Health Organization(WHO)decision to issue updated recommendations to prescribe ART to all individuals living with HIV,irrespective of age and CD4 cell count.Discussion:It is clear that the new 2015 WHO recommendations if followed,will change the face of the HIV epidemic and probably curb its burden over time.Implementation however,requires that health systems,especially those in low and middle-income settings,be ready to face this challenge on a large scale.HIV prevention and treatment are easy in theory yet hard in practice.The new WHO guidelines for initiation of ART regardless of CD4 cell count will lead to upfront increases in the costs of healthcare delivery as the goal is to treat all those now newly eligible for ART.Around 22 million people living with HIV qualify and will therefore require ART.Related challenges immediately follow:firstly,that everyone must be tested for HIV;secondly,that anyone who has had an HIV test should know their result and understand its significance;and,thirdly,that every person identified as HIV-positive should receive and remain on ART.The emergence of HIV drug resistant strains when treatment is started at higher CD4 cell count thresholds is a further concern as persons on HIV treatment for longer periods of time are at increased risk of intermittent medication adherence.Conclusions:The new WHO recommendations for ART are welcome,but lacking as they fail to consider meaningful solutions to the challenges inherent to implementation.They fail to incorporate actual strategies on how to disseminate and adopt these far-reaching guidelines,especially in sub-Saharan Africa,an area with weak healthcare infrastructures.Well-designed,high-quality research is needed to assess the feasibility,safety,acceptability,impact,and cost of innovations such as the universal voluntary testing and immediate treatment approaches,and broad consultation must address community,human rights,ethical,and political concerns.展开更多
文摘Introduction:Recently published large randomized controlled trials,START,TEMPRANO and HPTN 052 show the clinical benefit of early initiation of antiretroviral treatment(ART)in HIV-infected persons and in reducing HIV transmission.The trials influenced the World Health Organization(WHO)decision to issue updated recommendations to prescribe ART to all individuals living with HIV,irrespective of age and CD4 cell count.Discussion:It is clear that the new 2015 WHO recommendations if followed,will change the face of the HIV epidemic and probably curb its burden over time.Implementation however,requires that health systems,especially those in low and middle-income settings,be ready to face this challenge on a large scale.HIV prevention and treatment are easy in theory yet hard in practice.The new WHO guidelines for initiation of ART regardless of CD4 cell count will lead to upfront increases in the costs of healthcare delivery as the goal is to treat all those now newly eligible for ART.Around 22 million people living with HIV qualify and will therefore require ART.Related challenges immediately follow:firstly,that everyone must be tested for HIV;secondly,that anyone who has had an HIV test should know their result and understand its significance;and,thirdly,that every person identified as HIV-positive should receive and remain on ART.The emergence of HIV drug resistant strains when treatment is started at higher CD4 cell count thresholds is a further concern as persons on HIV treatment for longer periods of time are at increased risk of intermittent medication adherence.Conclusions:The new WHO recommendations for ART are welcome,but lacking as they fail to consider meaningful solutions to the challenges inherent to implementation.They fail to incorporate actual strategies on how to disseminate and adopt these far-reaching guidelines,especially in sub-Saharan Africa,an area with weak healthcare infrastructures.Well-designed,high-quality research is needed to assess the feasibility,safety,acceptability,impact,and cost of innovations such as the universal voluntary testing and immediate treatment approaches,and broad consultation must address community,human rights,ethical,and political concerns.
